+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.

Age: 55Years - 90YearsAll GendersPhase 3
162 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years with mild to severe Alzheimers Disease that includes moderate to severe psychosis symptoms. This Phase 3 study focuses on treating psychosis related to Alzheimers Disease using a randomized, double-blind, placebo-controlled design. Participants receive either KarXT or a placebo at specified doses on scheduled days. The study lasts up to 14 weeks, during which the impact of KarXT on hallucinations, delusions, and other neuropsychiatric symptoms is assessed. The research also monitors various safety measures and cognitive function throughout this period. During the study, participants undergo evaluations including neuropsychiatric inventories, clinical global impression scales, cognitive tests like the Mini-Mental State Examination and Alzheimers Disease Assessment Scale, as well as safety monitoring through laboratory tests, vital signs, ECGs, and assessments for adverse events. The primary outcome is the change in hallucinations and delusions score up to week 14, with ongoing safety and efficacy assessments throughout the treatment period.

Age: 55Years - 90YearsAll GendersPhase 3
296 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of KarXT in adult Japanese participants who are experiencing acute psychotic episodes of schizophrenia. This Phase 3 randomized study focuses on adults aged 18 to 65 with a confirmed diagnosis of schizophrenia based on DSM-5 criteria. The study aims to better understand how KarXT affects symptoms and overall severity of schizophrenia. Participants are assigned to receive either KarXT or a placebo in a double-blind, placebo-controlled manner for 5 weeks. After this period, a 52-week open-label extension allows all participants to receive KarXT to further assess long-term safety and effectiveness. Dosing follows specified schedules, and the study monitors changes in symptoms and adverse events throughout both phases. During the trial, participants will have regular assessments including symptom rating scales like the Positive and Negative Syndrome Scale PANSS and Clinical Global Impressions-Severity CGI-S. Safety evaluations include monitoring adverse events, physical exams, vital signs, laboratory tests, ECGs, and assessments for side effects such as movement disorders and suicidal ideation. The total study duration may extend up to about one year, including both the initial double-blind and the extension phases.

Age: 18Years - 65YearsAll GendersPhase 3
56 locations
L

Actively Recruiting

Researchers are investigating the long-term safety and effectiveness of a combined drug treatment using xanomeline tartratetrospium chloride in an immediate release capsule KarXT and xanomeline enteric capsules KarX-EC for people with agitation linked to Alzheimers Disease. This study is an open-label extension of earlier studies CN012-0023 and CN012-0024. It aims to understand how well these treatments work over time and monitor any side effects. Participants who completed the previous studies will receive specified doses of KarXT and KarX-EC according to a set schedule. This phase 3 study does not include a comparison group and all participants receive the combined treatment. The treatment period lasts approximately 30 weeks, during which the effects and safety of these medications will be observed. During the study, participants will be closely monitored for any adverse events, changes in cognitive function, movement disorders, vital signs, and other health measures. Assessments include scales like the Mini-Mental State Examination MMSE, Abnormal Involuntary Movement Scale AIMS, and others related to agitation and side effects. Safety checks such as lab tests, ECGs, and questionnaires will be regularly conducted. The total study duration for participants is about 30 weeks, with follow-up to evaluate overall treatment tolerability and impact.

Age: 55Years - 90YearsAll GendersPhase 3
252 locations
L

Actively Recruiting

Researchers are conducting a Phase 3 global, multicenter, 52-week open-label extension study to assess the long-term safety and tolerability of KarXT in people with psychosis associated with Alzheimers Disease. This study includes participants who have completed prior related studies, allowing continued evaluation of this treatment over an extended period. Participants receive KarXT capsules in various doses ranging from 202 mg to 66.76.67 mg three times daily. This extension study follows completion of earlier trials and continues treatment for up to 52 weeks to monitor long-term effects and safety. During the study, participants are monitored for treatment-emergent adverse events from the initial dose through 14 days after the last dose, totaling up to 54 weeks. Researchers track serious adverse events and withdrawals due to adverse events. The involvement lasts approximately one year, focusing on safety and tolerability assessments.

Age: 55Years - 90YearsAll GendersPhase 3
432 locations